Antiviral Activity of AZD7295 in HCV Carriers

A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00781976

Enrollment

Registered

2008-10-29

Start date

2008-11-30

Completion date

2010-03-31

Last updated

2010-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Brief summary

PK, safety study of AZD7295 in HCV carriers

Interventions

DRUGAZD7295

700mg per day maximum

DRUGPlacebo

matched placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* HCV carrier

Exclusion criteria

* concurrent medications

Design outcomes

Primary

Measure	Time frame
Plasma AZD7295 concentrations and pharmacokinetics	5 days

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026